Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

470
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer.

European urology focus·2026
Same author

The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.

The oncologist·2026
Same author

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Theranostics·2026
Same author

Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis.

European urology focus·2026
Same author

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
Same journal

With great cost comes great responsibility: who will own the rising costs of bladder cancer care?

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Sep 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and

James A Eastham1, Gregory B Auffenberg2, Daniel A Barocas3

  • 1Memorial Sloan Kettering Cancer Center, New York, New York.

The Journal of Urology
|May 10, 2022
PubMed
Summary
This summary is machine-generated.

This guideline provides evidence-based recommendations for managing clinically localized prostate cancer, focusing on risk assessment, staging, and treatment strategies. It serves as a foundational resource for clinicians to improve patient care.

Keywords:
Active surveillanceProstate cancerRadiation therapy for prostate cancerRadical prostatectomyShared decision making

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

392

Related Experiment Videos

Last Updated: Sep 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

392

Area of Science:

  • Urology
  • Oncology

Background:

  • Prostate cancer is a significant health concern.
  • Effective management of localized prostate cancer requires accurate risk assessment and staging.

Purpose of the Study:

  • To present Part I of a three-part guideline series on clinically localized prostate cancer.
  • To outline recommendations for risk assessment, staging, and risk-based management.

Main Methods:

  • A systematic review was conducted by an independent consultant.
  • Searches included Ovid MEDLINE, Cochrane databases, and reference lists of relevant articles.

Main Results:

  • Guideline statements were developed by the Clinically Localized Prostate Cancer Panel.
  • Recommendations cover risk assessment, staging, and risk-based management.

Conclusions:

  • The guideline aims to inform clinicians on managing localized prostate cancer.
  • Future research is crucial for advancing patient care.